



# Health Research Authority

## East of England - Cambridge East Research Ethics Committee

2 Redman Place  
London  
EC20 1JQ

Tel: 02071048181

**Please note: This is the favourable opinion of the REC only and does not allow the amendment to be implemented at NHS sites in England until the outcome of the HRA assessment has been confirmed.**

01 November 2024

Prof Peter Horby  
Professor of Emerging Infectious Diseases  
University of Oxford  
New Richards Building  
Old Road Campus  
Headington  
Oxford  
OX3 7LG

Dear Prof Horby

<b>Study title:</b>	<b>Randomised Evaluation of COVID-19 Therapy (RECOVERY)</b>
<b>REC reference:</b>	<b>20/EE/0101</b>
<b>Protocol number:</b>	<b>NDPHRECOVERY</b>
<b>EudraCT number:</b>	<b>2020-001113-21</b>
<b>Amendment number:</b>	<b>Substantial Amendment 36</b>
<b>Amendment date:</b>	<b>30 September 2024</b>
<b>IRAS project ID:</b>	<b>281712</b>

The above amendment was reviewed at the meeting of the Sub-Committee held in correspondence.

### **Ethical opinion**

The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on the basis described in the notice of amendment form and supporting documentation.

## Approved documents

The documents reviewed and approved at the meeting were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Annex 1: Clinical Trial Application Form [SA36 CTA form]	1	30 September 2024
Completed Amendment Tool [281712_Substantial Amendment 36]	1	30 September 2024
Cover Letter [RECOVERY SA36 REC cover letter]	1	30 September 2024
Letter from sponsor [RECOVERY SA36 Sponsor approval]	1	28 October 2024

## Membership of the Committee

The members of the Committee who took part in the review are listed on the attached sheet.

## Working with NHS Care Organisations

Sponsors should ensure that they notify the R&D office for the relevant NHS care organisation of this amendment in line with the terms detailed in the categorisation email issued by the lead nation for the study.

## Amendments related to COVID-19

We will update your research summary for the above study on the research summaries section of our website. During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you have not already done so, please register your study on a public registry as soon as possible and provide the HRA with the registration detail, which will be posted alongside other information relating to your project.

## Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

## HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities— see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

<b>IRAS Project ID - 281712:</b>	<b>Please quote this number on all correspondence</b>
----------------------------------	---

Yours sincerely

**Dr Alan Lamont**  
**Chair**  
Pp. Laura Fairman  
Approvals Administrator

E-mail: CambridgeEast.REC@hra.nhs.uk

*Enclosures: List of names and professions of members who took part in the review*

*Copy to: N/A RGEA, University of Oxford / Research Governance, Ethics and Assurance Confidentiality Advise Team*

**East of England - Cambridge East Research Ethics Committee**

**Attendance at Sub-Committee of the REC meeting held in correspondence.**

**Committee Members:**

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Dr Alan Lamont	Retired Consultant Oncologist	Yes	Chair
Dr Derek Prater	Pharmacist	Yes	

**Also in attendance:**

<i>Name</i>	<i>Position (or reason for attending)</i>
Mrs Laura Fairman	Approvals Administrator